BullFrog AI details 2025 progress, pharma partnerships, and 2026 catalysts

BullFrog AI Holdings, Inc.

Annual cash burn ~$6.2M; $10M equity line and ATM provide financing flexibility.
Multiple advanced pharma discussions for out-licensing or discovery collaborations with upfront/milestone payments.
Sygnature Discovery collaboration expected to generate revenue through 2028; sales kickoff in Sept 2025.
Eleison data from late-stage oncology collaboration accepted for ASCO GI Cancers Symposium Jan 9, 2026.
Launched bfPREP data prep tool; reduces data prep from months to days, enabling earlier engagement.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-029636
form_type: 8-K
ticker: BFRG
cik: 0001829247
company_name: BullFrog AI Holdings, Inc.
filed_at: 2025-12-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.662763+00:00
generated_at: 2026-05-16T12:01:06.130007+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.6
confidence: medium
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-029636
json_url: https://secwatch.observer/filing/0001493152-25-029636.json
markdown_url: https://secwatch.observer/filing/0001493152-25-029636.md
text_url: https://secwatch.observer/filing/0001493152-25-029636.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829247/000149315225029636/0001493152-25-029636-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829247/000149315225029636/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-029636

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.